Clinical trial · Observational
Real-world Insight Into Systemic Therapies for HCC: Single-center Study
Real-world Insight Into Systemic Therapies for Hepatocellular Carcinoma: a Comprehensive Single-center Study
NCT07814014CI-TRIAL-00126200HCCrecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 11, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260911-000001
Summary
Brief summary (as posted)
Real-world data from a single-center experience evaluating patients with hepatocellular carcinoma (HCC) receiving systemic therapies
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| HCC - Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- HCC patients on systemic therapies
- description
- 1. HCC patients receiving TKI (Sorafenib and Regrofenib 2. HCC patients receiving Atezolizumab with Bevacizumab 3. HCC patients receiving Tremelimumab with Durvalumab 4 -HCC patients With positive PCR HCV treating by DAAs with systemic therapy
Primary outcomes (3)
- measure
- overall survival (OS)
- timeFrame
- 1 year
- description
- time from initiation of systemic therapy to death from any cause
- measure
- treatment response
- timeFrame
- 1 year
- description
- m-RESIST analysis of the patients as its categories * CR - Complete response Disappearance of all arterial enhancement in all target lesions * PR - Partial response ≥30% decrease in the sum of diameters of viable tumor * SD - Stable disease Neither sufficient decrease for PR nor sufficient increase for PD * PD - Progressive disease ≥20% increase in the sum of viable tumor diameters, with an absolute increase of ≥5 mm, or appearance of new lesions/other progression criteria
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * patient with HCC * Child-Pugh class A, B7 * Performance state 0-1 (Eastern Cooperative Oncology Group (ECOG scale). * Barcelona Clinic Liver Cancer (BCLC) stage C or BCLC stage B with diffuse, infiltrative or extensive bilobar involvement or BCLC stage B with tumor progression after TACE. Exclusion Criteria: * patient with other tumor than HCC * Child-Turcotte-Pugh score B (8,9) and C. * Patients eligible for treatment other than systemic therapy according to Barcelona Clinic liver cancer.
References
Publications (0)
Data not yet available
No reference posted for this study.